{"title":"Quantifying an association between Doula Care with maternal and neonatal outcomes: A critical appraisal.","authors":"Avir Sarkar, Bijoya Mukherjee, Subrat Panda, Amiya Das, Priyanka Mondal, Suman Sandeep Samal","doi":"10.1016/j.ajog.2025.05.045","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.05.045","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genetics of Female Pelvic Organ Prolapse.","authors":"Si-Yun Li, Dong-Zhi Li","doi":"10.1016/j.ajog.2025.06.001","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.06.001","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Enhancing the Understanding of Female Sexual Function in Fertility Research.","authors":"Hongnan Shen, Jinguo Cheng","doi":"10.1016/j.ajog.2025.06.003","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.06.003","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144245740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dina O Eriksen, Kathrine D Lycke, Johnny Kahlert, Eva B Ostenfeld, Pernille T Jensen, Nicolas Wentzensen, Megan A Clarke, Anne Hammer
{"title":"Active surveillance of cervical intraepithelial neoplasia grade 2 is not associated with an increased risk of non-cervical anogenital HPV-related cancer and precancer a population-based cohort study.","authors":"Dina O Eriksen, Kathrine D Lycke, Johnny Kahlert, Eva B Ostenfeld, Pernille T Jensen, Nicolas Wentzensen, Megan A Clarke, Anne Hammer","doi":"10.1016/j.ajog.2025.05.039","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.05.039","url":null,"abstract":"<p><strong>Background: </strong>In recent years, many countries have implemented active surveillance (i.e., leaving the lesion untreated) as an option in younger women with cervical intraepithelial neoplasia grade 2 instead of excisional treatment. This is mainly due to the high regression rates of cervical intraepithelial neoplasia grade 2 and the observed increased risk associated with excisional treatment. Women with a previous history of excisional treatment for cervical precancer are at increased risk of subsequent anogenital cancer and precancer. For a full assessment of benefits and harms of active surveillance for CIN2, we investigated the risk of non-cervical anogenital cancers and precancers in women undergoing active surveillance.</p><p><strong>Objective: </strong>We aimed to investigate whether women undergoing active surveillance for cervical intraepithelial neoplasia grade 2 are at increased risk of vulva, vaginal, or anal cancer and precancer compared to women treated with loop electrosurgical excision procedure.</p><p><strong>Study design: </strong>We conducted a nationwide population-based cohort study in Denmark. We included all female residents diagnosed with incident cervical intraepithelial neoplasia grade 2 at age 18-40 during 1998-2020. The primary outcome was vulva, vaginal, or anal cancer or precancer. We stratified by age at CIN2 diagnosis (<30 years, ≥30 years), calendar year (1998-2012, 2013-2020), and index cytology (non-high-grade, high-grade). As secondary outcome, we considered low-grade lesions of the vulva, vagina, and anus. We used Cox regression to estimate hazard ratios (HR) of the outcomes with loop electrosurgical excision procedure as the reference group. We used inverse probability treatment weighting to calculate adjusted HR (aHR), considering age, calendar year, and index cytology as confounders.</p><p><strong>Results: </strong>Overall, 27,505 women with cervical intraepithelial neoplasia grade 2 were included; 12,507 (45.5%) underwent active surveillance, and 14,998 (54.5%) underwent loop electrosurgical excision procedure. A total of 162 women had a subsequent diagnosis of vulva, vaginal, or anal cancer or precancer. The cumulative risk after 10 years was 0.5% (95% CI (0.3-0.6)). We found no difference in risk between women undergoing active surveillance and those having a loop electrosurgical excision procedure (aHR=1.00 (95% CI 0.71-1.40)). Similar findings were observed when stratifying by age, year of diagnosis, and index cytology. We found that the risk of low-grade lesions of the vulva, vagina, and anus was lower in women undergoing active surveillance than in women treated with LEEP (aHR=0.75 (0.62-0.91).</p><p><strong>Conclusions: </strong>Active surveillance for cervical intraepithelial neoplasia grade 2 is not associated with an increased risk of non-cervical anogenital cancer and precancer compared to loop electrosurgical excision procedure. This finding contributes to the assessment of bene","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James Cheshire, Akanksha Garg, Paul Smith, Adam J Devall, Arri Coomarasamy, Rima K Dhillon-Smith
{"title":"Preconception and first trimester metformin on pregnancy outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis.","authors":"James Cheshire, Akanksha Garg, Paul Smith, Adam J Devall, Arri Coomarasamy, Rima K Dhillon-Smith","doi":"10.1016/j.ajog.2025.05.038","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.05.038","url":null,"abstract":"<p><strong>Objective: </strong>To explore the effects of preconception and first trimester metformin use on pregnancy outcomes in women with polycystic ovary syndrome (PCOS).</p><p><strong>Data sources: </strong>MEDLINE, Embase and the Cochrane Central Register of Controlled Trials were searched from database inception to August 1<sup>st</sup> 2024.</p><p><strong>Study eligibility criteria: </strong>Randomised controlled trials of metformin started preconception and continued at least until a positive pregnancy test compared to either placebo or no treatment in women with PCOS were included.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were performed. Pooled odds ratio (OR) with 95% confidence intervals (CI) were calculated for key outcomes: miscarriage (primary) and clinical pregnancy and live birth (secondary). Studies were assessed for quality using the Cochrane risk-of-bias tool for randomised trials (RoB-2) and Grading of Recommendations, Assessment, Development and Evaluation approach. Indirect comparisons were performed for all key outcomes, on the timing of metformin treatment, using the Bucher's technique.</p><p><strong>Results: </strong>A total of 12 trustworthy studies (1,708 women) were included in the meta-analysis; all graded low to moderate quality. Women who received preconception metformin which was continued throughout the first trimester showed higher clinical pregnancy rates (OR 1.57, 95% CI 1.11-2.23), a possible reduction in miscarriage (OR 0.64, 95% CI 0.32-1.25) and possible increase in live birth (OR 1.24, 95% CI 0.59-2.61), compared to either placebo or no treatment. In women who stopped metformin once pregnant, there was an increase in clinical pregnancy rate (OR 1.35, 95% CI 1.01-1.80), but also a suggestion of an increase in miscarriage rate (OR 1.46, 95% CI 0.73-2.90), compared to placebo or no treatment. Indirect comparisons of metformin continued through first trimester vs metformin stopped once pregnant consistently demonstrated a trend favouring the continuation of metformin: clinical pregnancy OR 1.16 (95% CI 0.74-1.83), miscarriage OR 0.44 (95% CI 0.17-1.16) and live birth OR 1.14 (95% CI 0.41-3.13).</p><p><strong>Conclusions: </strong>Continuing metformin treatment throughout the first trimester may reduce the risk of miscarriage and may increase live birth rates in women with PCOS. Continuation of metformin appears to have greater clinical benefit than stopping at positive pregnancy test. There is a need for further high-quality research.</p>","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144232945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Amniocentesis in pregnancies at or beyond 24 weeks.","authors":"Shehbano Syed","doi":"10.1016/j.ajog.2025.05.036","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.05.036","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacological treatment of hypertension in pregnancy: one does not fit all hemodynamic subtypes.","authors":"Michael Ceulemans, Wilfried Gyselaers","doi":"10.1016/j.ajog.2025.05.024","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.05.024","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Roni Zemet, Ronald J Wapner, Ignatia B VAN DEN Veyver
{"title":"Refining the Utility of Late Amniocentesis in High-Risk Pregnancies.","authors":"Roni Zemet, Ronald J Wapner, Ignatia B VAN DEN Veyver","doi":"10.1016/j.ajog.2025.05.037","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.05.037","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Concerns Regarding Calculator Validation and Health Equity.","authors":"Ann Ledbetter","doi":"10.1016/j.ajog.2025.05.033","DOIUrl":"https://doi.org/10.1016/j.ajog.2025.05.033","url":null,"abstract":"","PeriodicalId":7574,"journal":{"name":"American journal of obstetrics and gynecology","volume":" ","pages":""},"PeriodicalIF":8.7,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}